{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:52:37Z","timestamp":1793170357214,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Syst Biol Appl"],"DOI":"10.1038\/s41540-024-00461-2","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T06:00:41Z","timestamp":1732860041000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A mathematical framework for comparison of intermittent versus continuous adaptive chemotherapy dosing in cancer"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1664-8333","authenticated-orcid":false,"given":"Cordelia","family":"McGehee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"461_CR1","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader, N. et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383, 640\u2013649 (2020).","journal-title":"N. Engl. J. Med."},{"key":"461_CR2","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","volume":"26","author":"AB Mariotto","year":"2017","unstructured":"Mariotto, A. B., Etzioni, R., Hurlbert, M., Penberthy, L. & Mayer, M. Estimation of the number of women living with metastatic breast cancer in the united states. Cancer Epidemiol. Biomark. Prev. 26, 809\u2013815 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"461_CR3","doi-asserted-by":"crossref","unstructured":"Smith, I. Goals of treatment for patients with metastatic breast cancer. In Seminars in Oncology volume 33, pages 2\u20135. Elsevier, (2006).","DOI":"10.1053\/j.seminoncol.2005.07.030"},{"key":"461_CR4","first-page":"431","volume":"54","author":"S He","year":"1970","unstructured":"He, S. Implications of biochemical, cytokinetics, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother. Rep. 54, 431\u2013450 (1970).","journal-title":"Cancer Chemother. Rep."},{"key":"461_CR5","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan, D. et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Investig. 105, 1045\u20131047 (2000).","journal-title":"J. Clin. Investig."},{"key":"461_CR6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva, I., Waxman, D. J. & Klement, GiannoulaLakka Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 358, 100\u2013106 (2015).","journal-title":"Cancer Lett."},{"key":"461_CR7","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","volume":"11","author":"N Andr\u00e9","year":"2014","unstructured":"Andr\u00e9, N., Carr\u00e9, M. & Pasquier, E. Metronomics: towards personalized chemotherapy? Nat. Rev. Clin. Oncol. 11, 413\u2013431 (2014).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"461_CR8","doi-asserted-by":"publisher","first-page":"10051","DOI":"10.18632\/oncotarget.7067","volume":"7","author":"LucGT Morris","year":"2016","unstructured":"Morris, LucG. T. et al. Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. Oncotarget 7, 10051\u201310063 (2016).","journal-title":"Oncotarget"},{"key":"461_CR9","doi-asserted-by":"publisher","first-page":"10871","DOI":"10.1073\/pnas.1100299108","volume":"108","author":"AF Read","year":"2011","unstructured":"Read, A. F., Day, T. & Huijben, S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc. Natl Acad. Sci. 108, 10871\u201310877 (2011).","journal-title":"Proc. Natl Acad. Sci."},{"key":"461_CR10","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1158\/0008-5472.CAN-08-3658","volume":"69","author":"RA Gatenby","year":"2009","unstructured":"Gatenby, R. A., Silva, A. S., Gillies, R. J. & Frieden, B. R. Adaptive therapy. Cancer Res. 69, 4894\u20134903 (2009).","journal-title":"Cancer Res."},{"key":"461_CR11","doi-asserted-by":"publisher","first-page":"e76284","DOI":"10.7554\/eLife.76284","volume":"11","author":"J Zhang","year":"2022","unstructured":"Zhang, J., Cunningham, J., Brown, J. & Gatenby, R. Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes. eLife 11, e76284 (2022).","journal-title":"eLife"},{"key":"461_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-01968-5","volume":"8","author":"J Zhang","year":"2017","unstructured":"Zhang, J., Cunningham, J. J., Brown, J. S. & Gatenby, R. A. Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer. Nat. Commun. 8, 1\u20139 (2017).","journal-title":"Nat. Commun."},{"key":"461_CR13","doi-asserted-by":"publisher","first-page":"327ra24","DOI":"10.1126\/scitranslmed.aad7842","volume":"8","author":"PM Enriquez-Navas","year":"2016","unstructured":"Enriquez-Navas, P. M. et al. Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Sci. Transl. Med. 8, 327ra24\u2013327ra24 (2016).","journal-title":"Sci. Transl. Med."},{"key":"461_CR14","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ebiom.2019.09.023","volume":"48","author":"I Smalley","year":"2019","unstructured":"Smalley, I. et al. Leveraging transcriptional dynamics to improve braf inhibitor responses in melanoma. EBioMedicine 48, 178\u2013190 (2019).","journal-title":"EBioMedicine"},{"key":"461_CR15","doi-asserted-by":"publisher","first-page":"e84263","DOI":"10.7554\/eLife.84263","volume":"12","author":"J West","year":"2023","unstructured":"West, J. et al. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation. Elife 12, e84263 (2023).","journal-title":"Elife"},{"key":"461_CR16","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1089\/scd.2011.0477","volume":"21","author":"N Moore","year":"2012","unstructured":"Moore, N., Houghton, J. & Lyle, S. Slow-cycling therapy-resistant cancer cells. Stem cells Dev. 21, 1822\u20131830 (2012).","journal-title":"Stem cells Dev."},{"key":"461_CR17","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1096\/fasebj.2.7.3350243","volume":"2","author":"HJ Broxterman","year":"1988","unstructured":"Broxterman, H. J. et al. Induction by verapamil of a rapid increase in atp consumption in multidrug-resistant tumor cells. FASEB J. 2, 2278\u20132282 (1988).","journal-title":"FASEB J."},{"key":"461_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1158\/0008-5472.CAN-20-0806","volume":"81","author":"MaximilianAR Strobl","year":"2021","unstructured":"Strobl, MaximilianA. R. et al. Turnover modulates the need for a cost of resistance in adaptive therapy. Cancer Res. 81, 1135\u20131147 (2021).","journal-title":"Cancer Res."},{"key":"461_CR19","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-17-2649","volume":"78","author":"JA Gallaher","year":"2018","unstructured":"Gallaher, J. A., Enriquez-Navas, P. M., Luddy, K. A., Gatenby, R. A. & Anderson, A. R. A. Spatial heterogeneity and evolutionary dynamics modulate time to recurrence in continuous and adaptive cancer therapies. Cancer Res. 78, 2127\u20132139 (2018).","journal-title":"Cancer Res."},{"key":"461_CR20","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41559-021-01428-w","volume":"5","author":"Y Viossat","year":"2021","unstructured":"Viossat, Y. & Noble, R. A theoretical analysis of tumour containment. Nat. Ecol. Evol. 5, 826\u2013835 (2021).","journal-title":"Nat. Ecol. Evol."},{"key":"461_CR21","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1137\/0302013","volume":"2","author":"LM Sonneborn","year":"1964","unstructured":"Sonneborn, L. M. & Van Vleck, F. S. The bang-bang principle for linear control systems. J. Soc. Ind. Appl. Math. Ser. A: Control 2, 151\u2013159 (1964).","journal-title":"J. Soc. Ind. Appl. Math. Ser. A: Control"},{"key":"461_CR22","first-page":"341","volume":"21","author":"AJ Lotka","year":"1926","unstructured":"Lotka, A. J. Elements of physical biology. Sci. Prog. Twent. Century (1919-1933) 21, 341\u2013343 (1926).","journal-title":"Sci. Prog. Twent. Century (1919-1933)"},{"key":"461_CR23","doi-asserted-by":"publisher","first-page":"5225","DOI":"10.3390\/cancers14215225","volume":"14","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer. Cancers 14, 5225 (2022).","journal-title":"Cancers"},{"key":"461_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2023","unstructured":"Shore, N. D. et al. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostat. Canc. Prostatic Dis. 27, 192\u2013201 (2023).","journal-title":"Prostat. Canc. Prostatic Dis."},{"key":"461_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.ejca.2015.03.003","volume":"51","author":"X Garcia-Albeniz","year":"2015","unstructured":"Garcia-Albeniz, X. et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with psa-only relapse. an observational follow-up study. Eur. J. Cancer 51, 817\u2013824 (2015).","journal-title":"Eur. J. Cancer"},{"key":"461_CR26","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","volume":"17","author":"GM Duchesne","year":"2016","unstructured":"Duchesne, G. M. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising psa (trog 03.06 and vcog pr 01-03 [toad]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727\u2013737 (2016).","journal-title":"Lancet Oncol."},{"key":"461_CR27","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(17)30426-6","volume":"18","author":"GM Duchesne","year":"2017","unstructured":"Duchesne, G. M. et al. Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (trog 03.06 and vcog pr 01-03 [toad]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 18, 1192\u20131201 (2017).","journal-title":"Lancet Oncol."},{"key":"461_CR28","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1093\/jnci\/91.10.861","volume":"91","author":"CLL Trialists\u2019 CollaborativeGroup.","year":"1999","unstructured":"CLL Trialists\u2019 CollaborativeGroup. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J. Natl Cancer Inst. 91, 861\u2013868 (1999).","journal-title":"J. Natl Cancer Inst."},{"key":"461_CR29","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","volume":"34","author":"CD Herling","year":"2020","unstructured":"Herling, C. D. et al. Early treatment with fcr versus watch and wait in patients with stage binet a high-risk chronic lymphocytic leukemia (cll): a randomized phase 3 trial. Leukemia 34, 2038\u20132050 (2020).","journal-title":"Leukemia"},{"key":"461_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3934\/mbe.2021018","volume":"18","author":"K Bao","year":"2021","unstructured":"Bao, K. An elementary mathematical modeling of drug resistance in cancer. Math. Biosci. Eng. 18, 339\u2013353 (2021).","journal-title":"Math. Biosci. Eng."},{"key":"461_CR31","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3934\/mbe.2010.7.905","volume":"7","author":"C Tomasetti","year":"2010","unstructured":"Tomasetti, C. & Levy, D. An elementary approach to modeling drug resistance in cancer. Math. Biosci. Eng. MBE 7, 905 (2010).","journal-title":"Math. Biosci. Eng. MBE"},{"key":"461_CR32","doi-asserted-by":"publisher","first-page":"e1009418","DOI":"10.1371\/journal.pcbi.1009418","volume":"17","author":"T Kuosmanen","year":"2021","unstructured":"Kuosmanen, T. et al. Drug-induced resistance evolution necessitates less aggressive treatment. PLoS Comput. Biol. 17, e1009418 (2021).","journal-title":"PLoS Comput. Biol."},{"key":"461_CR33","doi-asserted-by":"publisher","first-page":"031501","DOI":"10.1088\/1478-3975\/ac4ee2","volume":"19","author":"J Foo","year":"2022","unstructured":"Foo, J. et al. Roadmap on plasticity and epigenetics in cancer. Phys. Biol. 19, 031501 (2022).","journal-title":"Phys. Biol."},{"key":"461_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-46926-x","volume":"9","author":"N Kumar","year":"2019","unstructured":"Kumar, N. et al. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations. Sci. Rep. 9, 10845 (2019).","journal-title":"Sci. Rep."},{"key":"461_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/CCI.18.00087","volume":"3","author":"JM Greene","year":"2019","unstructured":"Greene, J. M., Gevertz, J. L. & Sontag, E. D. Mathematical approach to differentiate spontaneous and induced evolution to drug resistance during cancer treatment. JCO Clin. cancer Inform. 3, 1\u201320 (2019).","journal-title":"JCO Clin. cancer Inform."},{"key":"461_CR36","doi-asserted-by":"publisher","first-page":"e1009348","DOI":"10.1371\/journal.pcbi.1009348","volume":"17","author":"T Cassidy","year":"2021","unstructured":"Cassidy, T., Nichol, D., Robertson-Tessi, M., Craig, M. & Anderson, AlexanderR. A. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance. PLOS Comput. Biol. 17, e1009348 (2021).","journal-title":"PLOS Comput. Biol."},{"key":"461_CR37","doi-asserted-by":"publisher","first-page":"e0243386","DOI":"10.1371\/journal.pone.0243386","volume":"15","author":"J Cunningham","year":"2020","unstructured":"Cunningham, J. et al. Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer. Plos one 15, e0243386 (2020).","journal-title":"Plos one"},{"key":"461_CR38","unstructured":"MA, M., Kim, J. Y. & Kim, E. Containing cancer with personalized minimum effective dose. BioRxiv pages 2022\u201303, (2022)."},{"key":"461_CR39","unstructured":"Wolfram Research, Inc. Mathematica, Version 14.0. Champaign, IL, (2024)."}],"container-title":["npj Systems Biology and Applications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00461-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00461-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T06:02:28Z","timestamp":1732860148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41540-024-00461-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["461"],"URL":"https:\/\/doi.org\/10.1038\/s41540-024-00461-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.19.580916","asserted-by":"object"}]},"ISSN":["2056-7189"],"issn-type":[{"value":"2056-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}